TY - JOUR
T1 - Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy
AU - Tada, Hayato
AU - Nomura, Akihiro
AU - Yoshimura, Kenichi
AU - Itoh, Hiroshi
AU - Komuro, Issei
AU - Yamagishi, Masakazu
AU - Takamura, Masayuki
AU - Kawashiri, Masa Aki
N1 - Funding Information:
M.Y. reports a research grant from Kowa Co., Ltd. H.I. reports grants and personal fees from Takeda Pharmaceutical Company Limited, and Mochida Pharmaceutical Co., Ltd. I.K. reports grants and personal fees from Takeda Pharmaceutical Company Limited. None of the other authors has anything to disclose.
Publisher Copyright:
© 2020 Japanese Circulation Society. All rights reserved.
PY - 2020/3
Y1 - 2020/3
N2 - Background: Few data specifically investigate associations between fasting/non-fasting triglycerides (TG) and cardiovascular (CV) events under statin therapy among Japanese diabetic patients. Methods and Results: We recruited 4,988 participants with diabetes from the EMPATHY study. Median follow-up was 3 years. We evaluated associations between serum fasting/non-fasting TG and first CV events in Cox-regression hazard models adjusted by classical risk factors. CV events were defined as (1) major adverse cardiac events (MACE) including myocardial infarction, stroke, or cardiac death; and (2) CV diseases (CVD) including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Fasting as well as non-fasting TG were associated with MACE (adjusted hazard ratio [HR]: 1.017 per 10 mg/dL; 95% confidence interval [CI]: 1.000–1.037; P=0.046, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.006–1.050; P=0.0091) and CVD (adjusted HR: 1.024 per 10 mg/dL; 95% CI: 1.011–1.038; P=4.4×10−3, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.010–1.046; P=4.9×10−3). Comparing the top quartile with the bottom quartile of non-fasting TG, adjusted HR significantly increased 5.18 (95% CI: 1.38–18.3, P=0.014) for MACE, and 2.40 (95% CI: 1.11–4.75, P=0.021) for CVD, while adjusted HR did not change when divided into quartile of fasting TG. Conclusions: Non-fasting TG could be considered as a substitute for fasting TG as a risk stratification for future CV events among Japanese diabetic patients.
AB - Background: Few data specifically investigate associations between fasting/non-fasting triglycerides (TG) and cardiovascular (CV) events under statin therapy among Japanese diabetic patients. Methods and Results: We recruited 4,988 participants with diabetes from the EMPATHY study. Median follow-up was 3 years. We evaluated associations between serum fasting/non-fasting TG and first CV events in Cox-regression hazard models adjusted by classical risk factors. CV events were defined as (1) major adverse cardiac events (MACE) including myocardial infarction, stroke, or cardiac death; and (2) CV diseases (CVD) including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Fasting as well as non-fasting TG were associated with MACE (adjusted hazard ratio [HR]: 1.017 per 10 mg/dL; 95% confidence interval [CI]: 1.000–1.037; P=0.046, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.006–1.050; P=0.0091) and CVD (adjusted HR: 1.024 per 10 mg/dL; 95% CI: 1.011–1.038; P=4.4×10−3, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.010–1.046; P=4.9×10−3). Comparing the top quartile with the bottom quartile of non-fasting TG, adjusted HR significantly increased 5.18 (95% CI: 1.38–18.3, P=0.014) for MACE, and 2.40 (95% CI: 1.11–4.75, P=0.021) for CVD, while adjusted HR did not change when divided into quartile of fasting TG. Conclusions: Non-fasting TG could be considered as a substitute for fasting TG as a risk stratification for future CV events among Japanese diabetic patients.
KW - Cardiovascular disease
KW - Residual risk
KW - Statins
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85092694148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092694148&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-19-0981
DO - 10.1253/circj.CJ-19-0981
M3 - Article
C2 - 32023582
AN - SCOPUS:85092694148
SN - 1346-9843
VL - 84
SP - 509
EP - 515
JO - Circulation Journal
JF - Circulation Journal
IS - 3
ER -
